Total salvage therapy for refractory acute promyelocytic leukemia (APL) including arsenic trioxide (AS203), all trans-retinoic acid (ATRA) and mylotarg [gemtuzumab ozogamicin]

Trial Profile

Total salvage therapy for refractory acute promyelocytic leukemia (APL) including arsenic trioxide (AS203), all trans-retinoic acid (ATRA) and mylotarg [gemtuzumab ozogamicin]

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2005

At a glance

  • Drugs Arsenic trioxide (Primary) ; Gemtuzumab ozogamicin (Primary) ; Tretinoin (Primary)
  • Indications Acute promyelocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top